LALPATHLAB Stock Overview
Operates laboratories for carrying out pathological investigations in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Dr. Lal PathLabs Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹2,946.25 |
| 52 Week High | ₹3,653.95 |
| 52 Week Low | ₹1,943.70 |
| Beta | 0.34 |
| 1 Month Change | -3.13% |
| 3 Month Change | -10.50% |
| 1 Year Change | 13.47% |
| 3 Year Change | -16.18% |
| 5 Year Change | 96.85% |
| Change since IPO | 257.12% |
Recent News & Updates
Recent updates
Analysts Are Updating Their Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Estimates After Its Second-Quarter Results
Oct 26
Capital Investment Trends At Dr. Lal PathLabs (NSE:LALPATHLAB) Look Strong
Oct 24Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Share Price Could Signal Some Risk
Oct 06These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely
Jul 28We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve
May 21What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You
May 01Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital
Apr 13These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely
Mar 06Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next
Feb 04Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price
Dec 28Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?
Nov 17Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around
Oct 12Here's Why Dr. Lal PathLabs (NSE:LALPATHLAB) Can Manage Its Debt Responsibly
Jul 07Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital
Jun 10Dr. Lal PathLabs (NSE:LALPATHLAB) Could Be Struggling To Allocate Capital
Feb 13Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?
Dec 29Dr. Lal PathLabs (NSE:LALPATHLAB) Will Want To Turn Around Its Return Trends
Sep 21These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Reasonably Well
Sep 01Dr. Lal PathLabs (NSE:LALPATHLAB) Will Pay A Dividend Of ₹6.00
Jul 31Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital
Jun 23Does This Valuation Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Imply Investors Are Overpaying?
Jun 11Shareholder Returns
| LALPATHLAB | IN Healthcare | IN Market | |
|---|---|---|---|
| 7D | -1.9% | -0.2% | -2.1% |
| 1Y | 13.5% | 44.5% | 22.5% |
Return vs Industry: LALPATHLAB underperformed the Indian Healthcare industry which returned 44.5% over the past year.
Return vs Market: LALPATHLAB underperformed the Indian Market which returned 22.5% over the past year.
Price Volatility
| LALPATHLAB volatility | |
|---|---|
| LALPATHLAB Average Weekly Movement | 3.9% |
| Healthcare Industry Average Movement | 5.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: LALPATHLAB has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: LALPATHLAB's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1949 | 4,099 | Shankha Banerjee | www.lalpathlabs.com |
Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers training programs.
Dr. Lal PathLabs Limited Fundamentals Summary
| LALPATHLAB fundamental statistics | |
|---|---|
| Market cap | ₹245.47b |
| Earnings (TTM) | ₹4.01b |
| Revenue (TTM) | ₹23.46b |
61.1x
P/E Ratio10.5x
P/S RatioIs LALPATHLAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LALPATHLAB income statement (TTM) | |
|---|---|
| Revenue | ₹23.46b |
| Cost of Revenue | ₹9.89b |
| Gross Profit | ₹13.57b |
| Other Expenses | ₹9.56b |
| Earnings | ₹4.01b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 48.18 |
| Gross Margin | 57.84% |
| Net Profit Margin | 17.11% |
| Debt/Equity Ratio | 2.0% |
How did LALPATHLAB perform over the long term?
See historical performance and comparisonDividends
0.6%
Current Dividend Yield62%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 23:52 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dr. Lal PathLabs Limited is covered by 44 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Prashant Nair | Ambit Capital |
| null null | Antique Stockbroking Ltd. |
| Harith Ahamed | Avendus Spark |